The American Journal of Medicine
Volume 120, Issue 2 , Pages 121-127 , February 2007

Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure

  • John R. Kapoor, MD, PhD

      Affiliations

    • Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, Calif
    • ,
  • Mark A. Perazella, MD, FACP

      Affiliations

    • Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Conn
    • Corresponding Author InformationRequests for reprints should be addressed to Mark A. Perazella, MD, FACP, Section of Nephrology, Department of Medicine, Yale University School of Medicine, FMP 107, 330 Cedar Street, New Haven, CT, 06511.

References 

  1. Heart Disease and Stroke Statistics—2006 Update (A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee). Circulation. 2006;113:e85
  2. Massie BM, Shah NB. The heart failure epidemic. Curr Opin Cardiol. 1996;11:221–226
  3. O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107–S112
  4. CMS national 2001 in-patient discharge data base MEDPAR, DRG 427.
  5. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002;106:416–422
  6. Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. 2006;47:13–18
  7. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–888
  8. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–246
  9. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–581
  10. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353–359
  11. Ewy GA. The abdominojugular test: technique and hemodynamic correlates. Ann Intern Med. 1988;109:456–460
  12. Nohira A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797–1804
  13. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691–695
  14. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833–838
  15. Silver MA, Maisel A, Yancy CW, et al. A clinical approach for the diagnostic, prognostic, screening, treatment, monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1–30
  16. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728–735
  17. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide (A new gold standard in predicting mortality in patients with advanced heart failure). Eur Heart J. 2003;24:1735–1743
  18. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Cardiol Fail. 2001;7:21–29
  19. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  20. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol. 2001;37:379–385
  21. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386–391
  22. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6:355–358
  23. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  24. Hsu H, Hickey RF, Forbes AR, et al. Morphine decreases peripheral vascular resistance and increases capacitance in man. Anesthesiology. 1979;50:98
  25. Peacock WF, Albert NM. Observation uniti management of heart failure. Emerg Med Clin North Am. 2001;19:209–232
  26. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–143
  27. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  28. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460–466
  29. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure (Activation of the neurohormonal axis). Ann Intern Med. 1985;103:1–6
  30. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–1315
  31. Costanzo MR, Heywood JT, DeMarco T, et al. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure. J Am Coll Cardiol. 2004;43:180A
  32. Enerman CL, Marco TD, Costanzo MR, et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with Acute Decompensated Heart Failure: insights from ADHERE Registry. J Card Fail. 2004;10:S116
  33. Stevenson LN. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail. 1999;1:251–257
  34. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–1172
  35. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393
  36. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756–1763
  37. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002;39:1623–1629
  38. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129–1135
  39. Mann T, Cohn PF, Holman BL, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Circulation. 1978;57:732–738
  40. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs. 2001;10:935–942
  41. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  42. Mills RM, Le Jemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999;34:155–162
  43. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253
  44. Peacock WF, Emerman CL. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients: the PROACTION trial. J Am Coll Cardiol. 2003;41:336A
  45. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  46. Silver MA, Horton DP, Ghali JK, et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798–803
  47. Sackner-Bernstein JD, Skopicki HA, Aaronson KD, et al. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  48. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  49. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–17G
  50. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987;59:1345–1350
  51. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73:III175–III183
  52. Weinstein J, Baim DS. The effects of acute dobutamine administration on myocardial metabolism and energetics. Heart Fail. 1996;2:110–116
  53. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2001;38:2101–2113
  54. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus docutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001;81:141–149
  55. Packer M, Carver JR, Rodeheffer RJ, et al. The PROMISE Study Research Group Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475
  56. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–1547
  57. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003
  58. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138:247–253
  59. O’Conner CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78–86
  60. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102–1108

PII: S0002-9343(06)00891-6

doi: 10.1016/j.amjmed.2006.05.066

The American Journal of Medicine
Volume 120, Issue 2 , Pages 121-127 , February 2007

Article Tools

* Image Usage & Resolution